{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:16:10Z","timestamp":1792826170179,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.smim.2025.101994","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:11:48Z","timestamp":1758701508000},"page":"101994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Oncolytic virotherapy: Sparking durable anti-tumor immunity through microenvironment modulation"],"prefix":"10.1016","volume":"80","author":[{"given":"Christoph F.","family":"Kollmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"van Montfoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cordelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olagnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2025.101994_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Rev. Med Virol."},{"key":"10.1016\/j.smim.2025.101994_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as Antigen-Agnostic cancer vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2025.101994_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.it.2020.03.003","article-title":"Immunotherapeutic potential of TGF-\u03b2 inhibition and oncolytic viruses","volume":"41","author":"Groeneveldt","year":"2020","journal-title":"Trends Immunol."},{"issue":"1979","key":"10.1016\/j.smim.2025.101994_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.smim.2025.101994_bib8","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus Medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.smim.2025.101994_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101994_bib12","unstructured":"Candel Therapeutics receives FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. News release. April 11, 2024. Accessed Dec 6, 2024. \u3008https:\/\/ir.candeltx.com\/news-releases\/news-release-details\/candel-therapeutics-receives-fda-orphan-drug-designation-can\u3009, (n.d.)."},{"key":"10.1016\/j.smim.2025.101994_bib13","unstructured":"Virogin Biotech recieves FDA orphan drug designation for VG161 for the treatment of Intrahepatic Cholangiocarcinoma. News release. Feb 12, 2023. Accessed Dec 6, 2024. \u3008https:\/\/virogin.com\/vg161-granted-for-fda-orphan-drug-designation\/\u3009, (n.d.)."},{"key":"10.1016\/j.smim.2025.101994_bib14","unstructured":"Imugene receives FDA orphan drug designation for CF33-hNIS for the treatment of cholangiocarcinoma. News release. Sept 18, 2024. Accessed Dec 6, 2024. \u3008https:\/\/app.sharelinktechnologies.com\/announcement\/asx\/32f19541537309fb869a824e78f3e5e3\u3009, (n.d.)."},{"key":"10.1016\/j.smim.2025.101994_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","author":"Gujar","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.smim.2025.101994_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.10","article-title":"Designing herpes viruses as oncolytics","volume":"2","author":"Peters","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101994_bib17","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.smim.2025.101994_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006561","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced\/metastatic epithelial cancer: a phase I clinical trial (SPICE)","volume":"11","author":"Fakih","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib19","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3390\/cancers12113219","article-title":"Past, present and future of oncolytic reovirus","volume":"12","author":"M\u00fcller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.smim.2025.101994_bib20","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1038\/s41467-024-53347-6","article-title":"Oral reovirus reshapes the gut microbiome and enhances anti-tumor immunity in colon cancer","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10637-015-0216-8","article-title":"The oncolytic virus, pelareorep, as a novel anti-cancer agent: a review","volume":"33","author":"Chakrabarty","year":"2015","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.smim.2025.101994_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","author":"Xu","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101994_bib24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/mt.2011.276","article-title":"The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers","volume":"20","author":"Parato","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/OV.S59640","article-title":"The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)","author":"Breitbach","year":"2015","journal-title":"Oncolytic Virother 4"},{"key":"10.1016\/j.smim.2025.101994_bib26","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.smim.2025.101994_bib27","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105219","article-title":"Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures","volume":"105","author":"Sch\u00e4fer","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.smim.2025.101994_bib29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/biomedicines10030562","article-title":"Molecular mechanisms of Anti-Neoplastic and immune stimulatory properties of oncolytic newcastle disease virus","volume":"10","author":"Schirrmacher","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.smim.2025.101994_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.101994_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/cancers13030544","article-title":"Measles virus as an oncolytic immunotherapy","volume":"13","author":"Engeland","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.smim.2025.101994_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3721","article-title":"Measles oncolytic virus as an immunotherapy for Recurrent\/Refractory pediatric medulloblastoma and atypical Teratoid\/Rhabdoid tumor: results from PNOC005","author":"Yu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2025.101994_bib33","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.smim.2025.101994_bib34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.smim.2025.101994_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OV.S154494","article-title":"Development and applications of oncolytic maraba virus vaccines","volume":"7","author":"Pol","year":"2018","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.smim.2025.101994_bib36","article-title":"Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Anti-tumor benefits of Anti-viral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","article-title":"Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire","volume":"17","author":"Haen","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092607","article-title":"The origin and immune recognition of tumor-specific antigens","volume":"12","author":"Apavaloaei","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.smim.2025.101994_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2025.101994_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.smim.2025.101994_bib42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/neuonc\/nov173","article-title":"Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling","volume":"18","author":"Cockle","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.826164","article-title":"Peptides-Coated oncolytic vaccines for cancer personalized Medicine","volume":"13","author":"Feola","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/2326-6066.CIR-17-0102","article-title":"Customized viral immunotherapy for HPV-Associated cancer","volume":"5","author":"Atherton","year":"2017","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.smim.2025.101994_bib45","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune cell topography predicts response to PD-1 blockade in cutaneous t cell lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101994_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1084887","article-title":"Towards a consensus definition of immune exclusion in cancer","volume":"14","author":"Tiwari","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib48","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib49","article-title":"Hot and cold tumors: immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.smim.2025.101994_bib50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2025.101994_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108707","article-title":"The tango between Cancer-Associated fibroblasts (CAFs) and immune cells in affecting immunotherapy efficacy in pancreatic cancer","volume":"24","author":"Stouten","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.smim.2025.101994_bib53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2025.101994_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1596006","article-title":"Oncolytic viruses: how \"lytic\" must they be for therapeutic efficacy?","volume":"8","author":"Davola","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101994_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2025.101994_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.831091","article-title":"Genetic modifications that expand oncolytic virus potency","volume":"9","author":"Cristi","year":"2022","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.smim.2025.101994_bib57","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/0008-5472.CAN-06-4260","article-title":"Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice","volume":"67","author":"Ganesh","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101994_bib58","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/gt.2011.184","article-title":"GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution","volume":"19","author":"Guedan","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101994_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib61","unstructured":"Theriva Biologics announces phase 1 trial data of VCN-01 in pediatric patients with refractory retinoblastoma. News release. April 2024. Accessed Dec 6. 2024. \u3008https:\/\/therivabio.com\/press_releases\/theriva-biologics-announces-positive-topline-data-from-investigator-sponsored-phase-1-trial-of-intravitreal-vcn-01-in-pediatric-patients-with-refractory-retinoblastoma\/\u3009, (n.d.)."},{"key":"10.1016\/j.smim.2025.101994_bib62","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anti-cancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.smim.2025.101994_bib63","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med"},{"key":"10.1016\/j.smim.2025.101994_bib64","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41417-022-00507-9","article-title":"Gastrointestinal cancer-associated fibroblasts expressing junctional adhesion Molecule-A are amenable to infection by oncolytic reovirus","volume":"29","author":"Harryvan","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101994_bib65","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41556-020-0527-7","article-title":"STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy","volume":"22","author":"Arwert","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.smim.2025.101994_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39204","article-title":"The implications of oncolytic viruses targeting fibroblasts in enhancing the antitumoural immune response","volume":"10","author":"Al-Obaidi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.smim.2025.101994_bib67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/mt.2013.240","article-title":"T-cell engager-armed oncolytic vaccinia virus significantly enhances anti-tumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib68","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101994_bib69","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omto.2023.02.002","article-title":"Reprogramming the tumor microenvironment leverages CD8+ t cell responses to a shared tumor\/self antigen in ovarian cancer","volume":"28","author":"Mistarz","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2025.101994_bib70","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.smim.2025.101994_bib71","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101994_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2020.07.007","article-title":"Tumour vasculature: friend or foe of oncolytic viruses?","volume":"56","author":"Santry","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.smim.2025.101994_bib73","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.smim.2025.101994_bib74","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1158\/1078-0432.CCR-04-0081","article-title":"Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12","volume":"10","author":"Wong","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.smim.2025.101994_bib75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/07357907.2012.654870","article-title":"Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model","volume":"30","author":"Goodwin","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.smim.2025.101994_bib76","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ijc.28747","article-title":"Oncolytic vaccinia virus demonstrates anti-angiogenic effects mediated by targeting of VEGF.","volume":"135","author":"Hou","year":"2014","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib77","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/1535-7163.MCT-18-0799","article-title":"Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways","volume":"18","author":"Tomita","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.smim.2025.101994_bib78","first-page":"1844","article-title":"Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers","volume":"59","author":"Deguchi","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.smim.2025.101994_bib79","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2025.101994_bib80","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12935-023-03099-y","article-title":"The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells","volume":"23","author":"Faghihkhorasani","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.smim.2025.101994_bib81","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/cgt.2012.49","article-title":"Treatment of breast cancer stem cells with oncolytic herpes simplex virus","volume":"19","author":"Li","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.smim.2025.101994_bib82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1479-5876-10-167","article-title":"Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells","volume":"10","author":"Wang","year":"2012","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.smim.2025.101994_bib83","article-title":"Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy","volume":"11","author":"Couturier","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.stem.2019.11.016","article-title":"Zika virus targets glioblastoma stem cells through a SOX2-Integrin \u03b1v\u03b25 axis","volume":"26","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.smim.2025.101994_bib85","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/neuonc\/nou359","article-title":"In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells","volume":"17","author":"McKenzie","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib86","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/neuonc\/not035","article-title":"Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin","volume":"15","author":"Zemp","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.smim.2025.101994_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008025","article-title":"Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a Double-Edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101994_bib90","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.smim.2025.101994_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164178","article-title":"Oncolytic viruses and immune checkpoint inhibitors: the \"hot\" new power couple","volume":"15","author":"Lovatt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.smim.2025.101994_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006518","article-title":"Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?","volume":"11","author":"Wan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib94","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic virus combination therapy: killing one bird with two stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/gt.2016.70","article-title":"Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy","volume":"24","author":"Ilett","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2025.101994_bib96","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/mt.2010.98","article-title":"Potentiating cancer immunotherapy using an oncolytic virus","volume":"18","author":"Bridle","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib97","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.101994_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib99","article-title":"An oncolytic virus delivering tumor-irrelevant bystander t cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy","author":"Chen","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib100","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.101994_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004464","article-title":"Preinduced reovirus-specific T-cell immunity enhances the anti-cancer efficacy of reovirus therapy","volume":"10","author":"Groeneveldt","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib102","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory t cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib103","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor t cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib104","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.101994_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.101994_bib106","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djy033","article-title":"Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy","volume":"110","author":"Kurokawa","year":"2018","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.smim.2025.101994_bib107","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.smim.2025.101994_bib108","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral t cell infiltration and improves Anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.101994_bib109","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2025.101994_bib110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","article-title":"Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase ib trial","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2025.101994_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma","volume":"9","author":"Malvehy","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.101994_bib112","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-24-1126","article-title":"A Dual-Armed oncolytic virus shows clinical efficacy in advanced solid cancers","volume":"30","author":"Silva-Pilipich","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2025.101994_bib113","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","article-title":"Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective","volume":"39","author":"Ramelyte","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2025.101994_bib114","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/0008-5472.CAN-19-2062","article-title":"Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy","volume":"80","author":"Tahtinen","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.smim.2025.101994_bib115","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:07:38Z","timestamp":1773126458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":115,"alternative-id":["S1044532325000661"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.101994","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic virotherapy: Sparking durable anti-tumor immunity through microenvironment modulation","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.101994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101994"}}